BeiGene, Ltd. (NASDAQ:ONC) has been in the news for various reasons, reflecting a mix of positive and challenging business activities. The biotech firm announced its future as
BeOne Medicines upon completing redomiciliation to Switzerland, marking a new chapter for its role in global oncology. The news followed a
Q4 earnings preview suggesting good revenue growth. Conversely, the company's stock experienced a 15.1% fall despite achieving GAAP profitability and raising 2026 guidance. This has prompted questions on the
bull case for the company. Other noteworthy news includes BeiGene’s announcement of its
Expanded InSysBio Collaboration on Clinical Trial Modeling and its deal with
Royalty Pharma worth up to $950 million for royalties from Amgen's lung cancer drug. BeiGene also made noteworthy advancements with a
Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer, and they were able to dismiss a patent asserted against them by Pharmacyclics. The company has reported a mixed set of Q1 2025 results, with some financial stats beating estimates while some falling short.
BeiGene, Ltd. News Analytics from Mon, 11 Jan 2021 08:00:00 GMT to Fri, 06 Mar 2026 17:22:15 GMT -
Rating 3
- Innovation 7
- Information 8
- Rumor -3
